Style Editor Docs
     
  • RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • US FDA IDE Pre-Submission
      • US FDA IDE Updates
    • Human Clinical Trials
  • IsoPet®
    • Regional Clinics
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • IsoPet® Therapy Pets
    • Veterinarians
    • Animal Studies
      • Canine Studies
      • Feline Studies
    • Our IsoPet® Mission
  • About Us
    • Management & Consultants
    • Advisory Boards
    • Contact - RadioGel™ | IsoPet®
  • Blog
  • Investors
    • Press Releases
    • Board of Directors
    • SEC Filings
    • Contact - Investor Relations
   Contact Us
  • RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • US FDA IDE Pre-Submission
      • US FDA IDE Updates
    • Human Clinical Trials
  • IsoPet®
    • Regional Clinics
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • IsoPet® Therapy Pets
    • Veterinarians
    • Animal Studies
      • Canine Studies
      • Feline Studies
    • Our IsoPet® Mission
  • About Us
    • Management & Consultants
    • Advisory Boards
    • Contact - RadioGel™ | IsoPet®
  • Blog
  • Investors
    • Press Releases
    • Board of Directors
    • SEC Filings
    • Contact - Investor Relations
  1. RadioGel™
  2. Precision Radionuclide Therapy (PRnT)

Precision Radionuclide Therapy (PRnT)

this is the  future of brachytherapy cancer treatment – the insertion of radioactive DEVICES directly into the tissue.

Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area. The product delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy.  This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.

 

According to Global Industry Analysts, by 2027 the Global brachytherapy market will reach $550 million (USD).  It is estimated that the U.S. market represents approximately half of the global market.  Vivos believes there are significant opportunities in prostate, breast, liver, pancreatic, head and neck cancers.  The 2019 U.S. estimated new cases according to the American Cancer Society are 240,000 prostate cancer, 235,000 breast cancer and 31,000 liver cancer.

Brachytherapy Product Technology Comparisons

Current technology versus the future

Based upon its studies and analyses, or general application of experience with current brachytherapy devices and Yttrium-90, Vivos believes that its brachytherapy products are likely to offer the following benefits, among others, for patients and medical professionals:

 

• Maximizing Therapeutic Index: The short-range beta particles emitted by Y-90 deliver radiation energy within a tight range. This enables radiation to be selectively delivered to target tissues while minimizing radiation dose to nearby normal tissues. High therapeutic indices imply that more radiation energy may be imparted to target tissues, with less radiation reaching adjacent normal tissues.

 

• Half Life: Y-90 has a half-life of just 2.7 days. Many traditional brachytherapy products use isotopes with longer half-lives such as 9.7 days for cesium-131, and sixty days for iodine-125.

 

• Optimized Delivery Method: Current brachytherapy devices place permanent metal seeds in the prostate by using up to 30 large needles. By contrast, Vivos’s Y-90 RadioGel™ device is designed to be administered in a minimally invasive procedure with small-gauge needles.

 

• No Permanent Seeds Remaining: Current brachytherapy devices place permanent metal seeds in the tumor. Vivos’ Y-90 RadioGel™ device utilizes a biodegradable, non-toxic polymer that is ultimately absorbed by the body. This eliminates the possibility of a long-term seed migration or other problems that may sometimes arise when seeds remain in the body.

 

• Good Safety Profile: Many traditional brachytherapy devices utilize isotopes that emit x-rays (akin to gamma radiation). X-rays or gamma radiation travels within and outside of the body and have long half-lives. Vivos’ brachytherapy products use the Yttrium-90 isotope, which is a beta-emitter. The Yttrium-90 beta-emissions travel only a short distance and has a short half life of 2.7 days.

 

• Potential Lower Cost: Yttrium-90 supplies are readily accessible and are relatively inexpensive. The elimination of the metal or glass enclosures used in traditional brachytherapy seeds greatly reduces manufacturing costs.

Subject to receipt of all required regulatory approvals from the FDA in the United States and analogous regulators outside of the United States, Vivos plans to introduce a new Y-90-based brachytherapy product line for a range of applications for the delivery of a prescribed dose of radiation to a target site.

  

Vivos, Inc.

Precision Radionuclide Therapy (PRnT)

OTCQB: RDGL

contact: info@radiogel.com


Home Page Cover Image: 

 

Veterinarian Dr. Michelle Myer from Vista Veterinarian Hospital in Kennewick, WA.

 

Seen here administering IsoPet® therapy to a feline suffering from a sarcoma.

RadioGel™ is a hydrogel liquid containing tiny yttrium-90 (90Y)  phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

IsoPet® Therapy Application(s)


Precision Radionuclide Therapy (PRnT)


Vivos Inc.
 - (OTCQB: RDGL) Investor Relations 

Contact

 

Main colors
   bg-primary
   bg-primary-light
   bg-primary-dark
   bg-secondary
   bg-secondary-dark
Template sections
   body
   top-header
   header
   content
Footer Styles
   background
   text color
   link color
   horizontal line
Buttons
   style 1
   style 2
   style 3
Other elements
  social icons
  navigation color
  subnav background
Mobile navigation
   background color
   navigation color
Template configurations
has-right-nav g-font
navigation styles
size-15 weight-400 snip-nav
content styles
form-white
footer styles
o-form color-white
Typography
Heading H1
weight-600
Heading H2
weight-600
Heading H3
weight-600
Buttons
weight-600 is-uppercase
Animations

Note:
All changes made here will be applied to your entire website.
is-switcher admin-only

RadioGel™ Logo

Precision Radionuclide Therapy (PRnT)

draggable-logo

About | Privacy Policy | Cookie Policy | Sitemap
© 2022 Vivos Inc. | RadioGel™ is a registered trademark | IsoPet® is a registered trademark
Log out | Edit
  • Precision Radionuclide Therapy (PRnT)
  • US FDA IDE Pre-Submission
  • Human Clinical Trials
  • Scroll to top